Market Cap 2.93B
Revenue (ttm) 7.87M
Net Income (ttm) -567.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,216.52%
Debt to Equity Ratio 0.16
Volume 6,080,100
Avg Vol 9,304,530
Day's Range N/A - N/A
Shares Out 342.83M
Stochastic %K 91%
Beta 1.58
Analysts Strong Sell
Price Target $10.25

Company Profile

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; a...

Industry: Biotechnology
Sector: Healthcare
Phone: 332 208 6102
Address:
1500 Broadway, Suite 1401, New York, United States
Night_Owl_Biotech
Night_Owl_Biotech Dec. 7 at 4:36 PM
The attached graph compares $NUVB analyst consensus revenue estimates to the same for $MRUS as of the day MRUS was acquired by $GMAB for an enterprise value of roughly $7.3B. We also noted MRUS management/BOD revenue projections were 2X higher than analysts (which may be absurd for all we know). Analysts forecast NUVB to generate roughly 80% of the revenues analysts project MRUS to generate at peak. NUVB market cap is roughly 40% of MRUS's EV. NUVB also has roughly $500MM cash at 9/30/2025. This is not investment advice as NUVB may be wildly overhyped for all we know. NUVB analyst revenue projections may also be fiction. We are merely sharing comparative data points. It is quite possible NUVB loses 70-80% of its market cap over the next 6 months. If NUVB is smart & pro-shareholder, it will seek an exit while its valuation has already soared. $XBI $IBB
0 · Reply
Bio_Invest101
Bio_Invest101 Dec. 7 at 2:59 PM
$NUVB So if we put @ak123456790 analysis of Ibtrozi worldwide market sales potentials and we could come to recognize the Stacked formula Dr Hung used to argue for his points? Then you think about my weekend freelancing on the SPRT/ARWR partnership deal format that could get us enough upfront cash plus milestones and royalties payments to support Safu getting through FDA approval and 2 yrs marketing after approval… you can see why Dr Hung won’t even think of selling NUVB right now. Be prepared for the long run if you’re a believer in Dr Hung And btw he owns 60 million common shares 18% total float, without even counting his RSU. He’s the founder and CEO. His buddy, The current NUVB chairman of BoD is from that Medivation BoD. So nobody could fire Hung. If he’s holding for a big pay day whenever, so do I. May I borrow a line from another poster “ In Hung, I trust” https://s27.q4cdn.com/855249317/files/doc_presentation/2025/12/Nuvation-Bio-Corporate-Presentation-December-2025.pdf
1 · Reply
Bio_Invest101
Bio_Invest101 Dec. 7 at 1:21 PM
$NUVB Great news indeed. https://en.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=567
1 · Reply
ak123456790
ak123456790 Dec. 7 at 1:03 PM
$NUVB More positive news regarding NUVB and Ibtrozi! Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List. What does that mean in simple words: China’s National Reimbursement Drug List (NRDL) officially added: DOVBLERON® = taletrectinib (Ibtrozi) for ROS1-positive NSCLC. This means: Taletrectinib is now reimbursed nationwide in China and: Patients pay very little out-of-pocket Usage explodes because China has a population of 1.4 billion Prescribers will immediately switch to the best drug in ROS1! Innovent has exclusive rights in China, Hong Kong, Macau and Taiwan. Anheart has received $55 million in connection with an upfront payment, $29 million additional regulatory milestones, $105 million → commercial milestones and Tiered royalties: mid-teen to low-twenties (%) which means 15-22% . This is the deal they made with Anheart before NUVB acquires them and now those money 134m will go to NUVB..
1 · Reply
AdiDasRom
AdiDasRom Dec. 7 at 6:15 AM
$NUVB YF "Innovent announces the inclusion of seven innovative drugs, including TYVYT New Indication and SYCUME, on the National List of Reimbursed Drugs in China" Nuvation dovblerom
0 · Reply
Kingcrab33333
Kingcrab33333 Dec. 6 at 7:38 PM
$NUVB $NUVB is heating up 🔥 Wave 2 breakout + massive ownership by insiders/institutions = low supply, high pressure. Momentum is REAL. If this clears $9, it could squeeze toward double digits fast.
0 · Reply
Shagg85
Shagg85 Dec. 6 at 7:37 PM
$NUVB I’d just like to thank Bio_invest101 for all the homework he does. Everyone should do their own DD, but he helps a lot of people with the research he does and I for one greatly appreciate it. Let’s let Dr. Hung make us rich. Thank you brother
2 · Reply
Bio_Invest101
Bio_Invest101 Dec. 6 at 7:09 PM
$NUVB Just my weekend freelance. I was in both SPRT and ARWR before & it’s a very fair and beneficial deal for both parties until SPRT got screwed by patients death & FDA dramas so CEO Doug sold the ARWR shares to pay for milestones …ARWR at $60 +now… My Points: 1) Dr Hung could get EU partner buying our stocks in public from $10-15 for 20-30M shares, just like SPRT did in ARWR deal. 2) The EU partnership could be simple on Introzi or big to include Safu just like SPRT agreed to pay for multiple milestones to ARWR. Agios sold Vora to Servier & done Royalty deal all b4 FDA approval. Why not Safu? Dr Hung left EU out for Safu trial? https://investor.agios.com/news-releases/news-release-details/agios-announces-905-million-purchase-agreement-vorasidenib this way Dr Hung could hang onto NUVB for much longer time without pressure to sell it soon. https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-announces-closing-global-license-and
2 · Reply
JFais
JFais Dec. 6 at 4:21 PM
$NUVB (L) From Weekly Recap
0 · Reply
2Pennies4Tendies
2Pennies4Tendies Dec. 6 at 4:17 PM
0 · Reply
Latest News on NUVB
Nuvation Bio: A Strong Company Now Fairly Priced

Nov 29, 2025, 4:37 AM EST - 8 days ago

Nuvation Bio: A Strong Company Now Fairly Priced


Nuvation Bio to Participate in Upcoming Investor Conferences

Nov 26, 2025, 4:05 PM EST - 10 days ago

Nuvation Bio to Participate in Upcoming Investor Conferences


Nuvation Bio: Ibtrozi's Rollout So Far Confirms Bullish Case

Nov 7, 2025, 5:23 PM EST - 4 weeks ago

Nuvation Bio: Ibtrozi's Rollout So Far Confirms Bullish Case


Nuvation Bio Inc. (NUVB) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 9:46 PM EST - 4 weeks ago

Nuvation Bio Inc. (NUVB) Q3 2025 Earnings Call Transcript


Why Nuvation Bio Stock Is Skyrocketing Today

Sep 30, 2025, 11:33 AM EDT - 2 months ago

Why Nuvation Bio Stock Is Skyrocketing Today


3 Of My Favorite Biotech Stocks Under $10

Sep 29, 2025, 1:15 PM EDT - 2 months ago

3 Of My Favorite Biotech Stocks Under $10

DVAX FOLD MRNA PFE


Nuvation Bio: A Rare Gem In The Risky Biotech Space

Sep 15, 2025, 12:27 PM EDT - 2 months ago

Nuvation Bio: A Rare Gem In The Risky Biotech Space


Top 2 Health Care Stocks That May Plunge This Month

Sep 5, 2025, 10:39 AM EDT - 3 months ago

Top 2 Health Care Stocks That May Plunge This Month

ESPR


Nuvation Bio: What To Expect From IBTROZI Launch?

Aug 28, 2025, 12:16 PM EDT - 3 months ago

Nuvation Bio: What To Expect From IBTROZI Launch?


NUVB Sales Jump 1,043% on Drug Launch

Aug 7, 2025, 10:40 AM EDT - 4 months ago

NUVB Sales Jump 1,043% on Drug Launch


US FDA approves Nuvation Bio's lung cancer therapy

Jun 11, 2025, 1:45 PM EDT - 6 months ago

US FDA approves Nuvation Bio's lung cancer therapy


Nuvation Bio Inc. (NUVB) Q1 2025 Earnings Call Transcript

May 11, 2025, 10:05 PM EDT - 7 months ago

Nuvation Bio Inc. (NUVB) Q1 2025 Earnings Call Transcript


Night_Owl_Biotech
Night_Owl_Biotech Dec. 7 at 4:36 PM
The attached graph compares $NUVB analyst consensus revenue estimates to the same for $MRUS as of the day MRUS was acquired by $GMAB for an enterprise value of roughly $7.3B. We also noted MRUS management/BOD revenue projections were 2X higher than analysts (which may be absurd for all we know). Analysts forecast NUVB to generate roughly 80% of the revenues analysts project MRUS to generate at peak. NUVB market cap is roughly 40% of MRUS's EV. NUVB also has roughly $500MM cash at 9/30/2025. This is not investment advice as NUVB may be wildly overhyped for all we know. NUVB analyst revenue projections may also be fiction. We are merely sharing comparative data points. It is quite possible NUVB loses 70-80% of its market cap over the next 6 months. If NUVB is smart & pro-shareholder, it will seek an exit while its valuation has already soared. $XBI $IBB
0 · Reply
Bio_Invest101
Bio_Invest101 Dec. 7 at 2:59 PM
$NUVB So if we put @ak123456790 analysis of Ibtrozi worldwide market sales potentials and we could come to recognize the Stacked formula Dr Hung used to argue for his points? Then you think about my weekend freelancing on the SPRT/ARWR partnership deal format that could get us enough upfront cash plus milestones and royalties payments to support Safu getting through FDA approval and 2 yrs marketing after approval… you can see why Dr Hung won’t even think of selling NUVB right now. Be prepared for the long run if you’re a believer in Dr Hung And btw he owns 60 million common shares 18% total float, without even counting his RSU. He’s the founder and CEO. His buddy, The current NUVB chairman of BoD is from that Medivation BoD. So nobody could fire Hung. If he’s holding for a big pay day whenever, so do I. May I borrow a line from another poster “ In Hung, I trust” https://s27.q4cdn.com/855249317/files/doc_presentation/2025/12/Nuvation-Bio-Corporate-Presentation-December-2025.pdf
1 · Reply
Bio_Invest101
Bio_Invest101 Dec. 7 at 1:21 PM
$NUVB Great news indeed. https://en.innoventbio.com/InvestorsAndMedia/PressReleaseDetail?key=567
1 · Reply
ak123456790
ak123456790 Dec. 7 at 1:03 PM
$NUVB More positive news regarding NUVB and Ibtrozi! Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List. What does that mean in simple words: China’s National Reimbursement Drug List (NRDL) officially added: DOVBLERON® = taletrectinib (Ibtrozi) for ROS1-positive NSCLC. This means: Taletrectinib is now reimbursed nationwide in China and: Patients pay very little out-of-pocket Usage explodes because China has a population of 1.4 billion Prescribers will immediately switch to the best drug in ROS1! Innovent has exclusive rights in China, Hong Kong, Macau and Taiwan. Anheart has received $55 million in connection with an upfront payment, $29 million additional regulatory milestones, $105 million → commercial milestones and Tiered royalties: mid-teen to low-twenties (%) which means 15-22% . This is the deal they made with Anheart before NUVB acquires them and now those money 134m will go to NUVB..
1 · Reply
AdiDasRom
AdiDasRom Dec. 7 at 6:15 AM
$NUVB YF "Innovent announces the inclusion of seven innovative drugs, including TYVYT New Indication and SYCUME, on the National List of Reimbursed Drugs in China" Nuvation dovblerom
0 · Reply
Kingcrab33333
Kingcrab33333 Dec. 6 at 7:38 PM
$NUVB $NUVB is heating up 🔥 Wave 2 breakout + massive ownership by insiders/institutions = low supply, high pressure. Momentum is REAL. If this clears $9, it could squeeze toward double digits fast.
0 · Reply
Shagg85
Shagg85 Dec. 6 at 7:37 PM
$NUVB I’d just like to thank Bio_invest101 for all the homework he does. Everyone should do their own DD, but he helps a lot of people with the research he does and I for one greatly appreciate it. Let’s let Dr. Hung make us rich. Thank you brother
2 · Reply
Bio_Invest101
Bio_Invest101 Dec. 6 at 7:09 PM
$NUVB Just my weekend freelance. I was in both SPRT and ARWR before & it’s a very fair and beneficial deal for both parties until SPRT got screwed by patients death & FDA dramas so CEO Doug sold the ARWR shares to pay for milestones …ARWR at $60 +now… My Points: 1) Dr Hung could get EU partner buying our stocks in public from $10-15 for 20-30M shares, just like SPRT did in ARWR deal. 2) The EU partnership could be simple on Introzi or big to include Safu just like SPRT agreed to pay for multiple milestones to ARWR. Agios sold Vora to Servier & done Royalty deal all b4 FDA approval. Why not Safu? Dr Hung left EU out for Safu trial? https://investor.agios.com/news-releases/news-release-details/agios-announces-905-million-purchase-agreement-vorasidenib this way Dr Hung could hang onto NUVB for much longer time without pressure to sell it soon. https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-announces-closing-global-license-and
2 · Reply
JFais
JFais Dec. 6 at 4:21 PM
$NUVB (L) From Weekly Recap
0 · Reply
2Pennies4Tendies
2Pennies4Tendies Dec. 6 at 4:17 PM
0 · Reply
Bio_Invest101
Bio_Invest101 Dec. 6 at 2:24 PM
$NUVB Ibtrozi China national drug listing news tomorrow or Monday https://flcube.com/?p=49943
0 · Reply
Bio_Invest101
Bio_Invest101 Dec. 6 at 12:26 PM
$NUVB Look a bit further ahead of M&A in2026 and 2-3 yrs left of the Trump administration favorites policy, IMO, NUVB is in the state of hunting for good small or midsize of CNS/oncology projects and that seems getting much harder right now than of 1-2 yrs ago when Dr Hung took over Anheart in $260 M worth of stocks, no cash. An Unbelievable deal proven Hung is not only good to sell his own drugs and business but also has a very good reputation in finding good deal around the world. It makes us rethink what the EU partnership will focus on and the 2 strategy moves he recently made in stopping trials of Safu H2H with Vora and NUV1511. Huge savings. I don’t think Hung’s attentions are selling NUVB in near term but pipelines building. What and where will he land the next target ? China is still hot in biotech RD. will he still find another gold nugget like Anheart deal in favorable terms? https://www.fiercepharma.com/pharma/biopharma-dealmaking-landscape-and-what-expect-2026
1 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 5 at 11:24 PM
Enter: $NUVB Calls Strike Price: $10 Expiry Date: JAN 16 2026 Buy in Price: $0.40 - $0.50 Sell Price: $0.72 Profit : +80% (Turn every $1 into $1.80) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
jones_
jones_ Dec. 5 at 9:57 PM
$NUVB added
0 · Reply
Shagg85
Shagg85 Dec. 5 at 8:51 PM
$NUVB Big push into close
0 · Reply
Thatbull92
Thatbull92 Dec. 5 at 8:14 PM
0 · Reply
searchthealley
searchthealley Dec. 5 at 8:00 PM
$NUVB ohyaa gj ❤️
1 · Reply
StockKilla77
StockKilla77 Dec. 5 at 7:43 PM
$NUVB 8.70?? Wow happy new 52 week high gang! Feels like a new one everyday 🚀 wouldn’t be surprised if we aren’t at a new ath which is above $15.23 prob end of q1 or beginning to mid q2
0 · Reply
JanetBSmellin
JanetBSmellin Dec. 5 at 6:58 PM
2 · Reply
1Knevrenuff
1Knevrenuff Dec. 5 at 6:37 PM
$NUVB ...8.60 soft barometer break through after coming off 52 week high of 8.50 then slight pullback...66m shorts
0 · Reply
Kingcrab33333
Kingcrab33333 Dec. 5 at 6:37 PM
0 · Reply
1Knevrenuff
1Knevrenuff Dec. 5 at 6:35 PM
$NUVB ...so much going on...forgot about you...March $10C's printing!!
0 · Reply